174 related articles for article (PubMed ID: 28669737)
1. Savolitinib for MET-driven papillary renal cell carcinoma.
Gilbert JA
Lancet Oncol; 2017 Aug; 18(8):e440. PubMed ID: 28669737
[No Abstract] [Full Text] [Related]
2. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L
JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK
J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771
[TBL] [Abstract][Full Text] [Related]
4. Savolitinib Heads for Phase III Trial in PRCC.
Cancer Discov; 2017 Sep; 7(9):OF4. PubMed ID: 28724523
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
6. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
[No Abstract] [Full Text] [Related]
7. First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Gan HK; Millward M; Hua Y; Qi C; Sai Y; Su W; Wang J; Zhang L; Frigault MM; Morgan S; Yang L; Lickliter JD
Clin Cancer Res; 2019 Aug; 25(16):4924-4932. PubMed ID: 30952639
[TBL] [Abstract][Full Text] [Related]
8. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN
Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib improves clinical outcomes in renal cancer.
Das M
Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
[No Abstract] [Full Text] [Related]
10. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Diamond JR; Salgia R; Varella-Garcia M; Kanteti R; LoRusso PM; Clark JW; Xu LG; Wilner K; Eckhardt SG; Ching KA; Lira ME; Schoenmakers EF; Christensen JG; Camidge DR
J Clin Oncol; 2013 Jun; 31(16):e254-8. PubMed ID: 23610116
[No Abstract] [Full Text] [Related]
11. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri TK; Vaishampayan U; Rosenberg JE; Logan TF; Harzstark AL; Bukowski RM; Rini BI; Srinivas S; Stein MN; Adams LM; Ottesen LH; Laubscher KH; Sherman L; McDermott DF; Haas NB; Flaherty KT; Ross R; Eisenberg P; Meltzer PS; Merino MJ; Bottaro DP; Linehan WM; Srinivasan R
J Clin Oncol; 2013 Jan; 31(2):181-6. PubMed ID: 23213094
[TBL] [Abstract][Full Text] [Related]
12. In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2016 Jul; 58(1499):e97. PubMed ID: 27403787
[No Abstract] [Full Text] [Related]
13. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
14. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Schuller AG; Barry ER; Jones RD; Henry RE; Frigault MM; Beran G; Linsenmayer D; Hattersley M; Smith A; Wilson J; Cairo S; Déas O; Nicolle D; Adam A; Zinda M; Reimer C; Fawell SE; Clark EA; D'Cruz CM
Clin Cancer Res; 2015 Jun; 21(12):2811-9. PubMed ID: 25779944
[TBL] [Abstract][Full Text] [Related]
15. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
Mehta A; Sonpavde G; Escudier B
Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
[TBL] [Abstract][Full Text] [Related]
16. Savolitinib: First Approval.
Markham A
Drugs; 2021 Sep; 81(14):1665-1670. PubMed ID: 34455538
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
18. Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
Yaman S; Bilgin B; Şendur MA; Hızal M; Akıncı MB; Yalçın B
Future Oncol; 2019 Mar; 15(9):925-927. PubMed ID: 30854890
[No Abstract] [Full Text] [Related]
19. A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma.
Patel HV; Srivastava A; Srinivasan R; Singer EA
Curr Opin Oncol; 2021 May; 33(3):212-220. PubMed ID: 33818540
[TBL] [Abstract][Full Text] [Related]
20. Third-Line Treatment Options for Kidney Cancer.
Posadas EM; Limvorasak S; Figlin RA
Oncology (Williston Park); 2016 Sep; 30(9):813-5. PubMed ID: 27633411
[No Abstract] [Full Text] [Related]
[Next] [New Search]
